Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs

Autor: Hidetaka Nishida, Hideo Akiyoshi, Toshiyuki Tanaka, Naoki Miura, Keiichiro Mie, Hiroki Yamazaki
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Indoles
medicine.medical_treatment
Standard Article
030204 cardiovascular system & hematology
Gastroenterology
0403 veterinary science
chemistry.chemical_compound
0302 clinical medicine
Renal cell carcinoma
Neoplasms
Dog Diseases
lcsh:Veterinary medicine
Hazard ratio
Small Intestinal Adenocarcinoma
04 agricultural and veterinary sciences
Standard Articles
Vascular endothelial growth factor
Treatment Outcome
medicine.anatomical_structure
Oncology
Chemotherapy
Adjuvant
Adenocarcinoma
Female
Adjuvant
medicine.medical_specialty
040301 veterinary sciences
Anal sac adenocarcinoma
03 medical and health sciences
Dogs
Internal medicine
medicine
Animals
tumor microenvironment
Pyrroles
Carcinoma
Renal Cell
Retrospective Studies
Lung
adenocarcinoma
General Veterinary
business.industry
postoperative adjuvant treatment
medicine.disease
Vascular Endothelial Growth Factor Receptor-2
chemistry
lcsh:SF600-1100
SMALL ANIMAL
Neoplasm Recurrence
Local
business
toceranib phosphate
Zdroj: Journal of Veterinary Internal Medicine, Vol 34, Iss 3, Pp 1272-1281 (2020)
Journal of Veterinary Internal Medicine
ISSN: 0891-6640
1939-1676
Popis: Background Toceranib phosphate (TOC) could be made widely available for treating tumors in dogs if evidence shows that TOC inhibits recurrence after surgery. Objectives To investigate how postoperative adjuvant treatment with TOC modulates the tumor microenvironment (TME), by assessing effects on angiogenic activity, tumor-infiltrating regulatory T cells (Tregs), and intratumoral hypoxia. Animals Ninety-two client-owned dogs were included: 28 with apocrine gland anal sac adenocarcinoma, 24 with small intestinal adenocarcinoma, 22 with lung adenocarcinoma, and 18 with renal cell carcinoma. Methods Retrospective, multicenter study comparing time to progression (TTP) between 42 dogs treated by surgery and TOC and 50 dogs treated by surgery alone. Differences were analyzed in the expression of vascular endothelial growth factor receptor-2 (VEGFR2) and the number of Foxp3+ Tregs and hypoxia-inducible factor (HIF)-1α+ cells in tumor tissues sampled at the first and second (recurrence) surgeries. Results Median TTP for dogs treated by surgery and TOC (360 days) was higher than that for dogs treated by surgery alone (298 days; hazard ratio, 0.82; 95% confidence interval [CI], 0.65-0.96; P = .02). In dogs treated by surgery and TOC, VEGFR2 expression and the number of Tregs and HIF-1α+ cells were significantly lower in tissues sampled at the second surgery than in those sampled after the first surgery. In dogs treated by surgery alone, significant differences were found between samples from the 2 surgeries. Conclusions and clinical importance Toceranib phosphate could prove to be a useful postoperative adjuvant treatment because of its modulation of the TME.
Databáze: OpenAIRE
Externí odkaz: